Ecnoglutide Guide
XANO Pharmaceuticals
Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..
XANO Pharmaceuticals\' GLP-1 Receptor Agonist
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options. Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Ecnoglutide?
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In Phase 2 trials, it demonstrated up to approximately 16% weight loss over 24 weeks in adults with obesity. Its development adds to the growing global pipeline of GLP-1 therapies aiming to provide more accessible treatment options.
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
Clinical Data
Side Effects
Vital Protocol FAQs
Guide FAQs
Complete guide to Ecnoglutide. Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist developed by Sciwind Biosciences / XANO Pharmaceuticals. In ..
Yes. Shotlee supports tracking Ecnoglutide doses, side effects, and health metrics. It is free to use.
Track Your Ecnoglutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Ecnoglutide
Pfizer's Xianweiying GLP-1 Weight Loss Drug Pre-Order in China
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
5 min read
Pfizer's China GLP-1 Deal and BRAFTOVI Oncology Approval
Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.
5 min read
Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
6 min read